Sputum-derived Cellular Targets After Xolair (Omalizumab)
Status:
Terminated
Trial end date:
2018-07-19
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to identify additional mechanisms of action of
omalizumab that will lead to improved stratification of patients for treatment. Understanding
the response of specific innate immune effector cells in the lung can provide clues to these
questions. Investigators will use non-invasive measures of a discrete cell population to
examine the downstream effects of omalizumab treatment in the lung. Information derived from
these studies will help clarify mechanisms of action of omalizumab and help identify
potential tools for patient endotyping and stratification for therapeutic interventions.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health